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Family Practice Inquiries Network (FPIN). Members of the network select questions based on 
their relevance to family medicine. Answers are drawn from an approved set of evidence-based 
resources and undergo peer review. The strength of recommendations and the level of evidence 
for individual studies are rated using criteria developed by the Evidence-Based Medicine 
Working Group (http://www.cebm.net/levels_of_evidence.asp). 
This series of Clinical Inquiries is coordinated for American Family Physician by John Epling, 
M.D., State University of New York Upstate Medical University, Syracuse, N.Y. The complete 
database of evidence-based questions and answers is copyrighted by FPIN. If you are interested 
in submitting questions to be answered or writing answers for this series, go to 
http://www.fpin.org or contact CI2Editor@fpin.org. 
Searchable Question 
Does screening with mammography reduce breast cancer mortality in women 40 to 49 years of 
age? 
Evidence-Based Answer 
While there is strong agreement among experts and evidence in the literature to recommend that 
women 50 to 69 years of age undergo screening with mammography for breast cancer, the 
question of screening women 40 to 49 years of age is controversial. 
The results of most studies suggest that screening with mammography in women 40 to 49 years 
of age may reduce mortality from breast cancer, but these reductions are small (i.e., fewer than 1 
in 10,000 per year).1-8 [Strength of recommendation: B, based on meta-analysis and systematic 
review of randomized controlled trials (RCTs) with inconsistent findings] 
The balance of benefits and potential harms (i.e., cost, unnecessary biopsies, anxiety) is less 
favorable for women in their forties than for women older than 50. The precise age at which the 
potential benefits justify the possible harm is a subjective choice. 
There is not enough evidence to recommend optimal intervals for screening with mammography 
in women in their forties.[Strength of recommendation: C, based on extrapolations from studies 
with inconsistent findings] 
Evidence Summary 
Of the eight published RCTs on breast cancer screening using mammography, seven included 
women in their forties.1-5 Only one study4 was specifically designed to evaluate screening in 
this age group. Data from these trials have been analyzed in at least eight meta-analyses. The 
conclusions vary among the meta-analyses because of the varying length of follow-up in the 
analyses, or exclusions related to methodologic concerns.6 
A Cochrane review of the seven studies concluded that current evidence does not show an 
overall survival benefit from mass screening for breast cancer and is inconclusive for breast 
cancer mortality.7 Among women in their forties, the review reported a relative risk for death 
from breast cancer of 1.03 (confidence interval [CI], 0.77 to 1.38), although this risk was based 
on data from only two of the trials because of bias concerns and inappropriate methods used in 
the remaining trials. 
The U.S. Preventive Services Task Force (USPSTF) conducted a meta-analysis of six of the 
studies (excluding one1 of the seven trials for methodologic reasons) to evaluate the 
effectiveness of screening women in their forties with mammography.6 The results of the meta-
analysis found a relative risk of 0.85 (credible interval [CrI], 0.79 to 0.99), and a 15 percent 
relative risk reduction. (CrI is a Bayesian statistical distribution, similar to the confidence 
interval.) The number of 40-year-old women who would have to be screened for 14 years to 
prevent one death from breast cancer was 1,792 (CrI, 764 to 10,540). 
With a longer period of observation, there appears to be an increasing benefit from screening 
among women in their forties. While some earlier meta-analyses showed no benefit,8 subsequent 
meta-analyses have incorporated more recent study results and have demonstrated reductions in 
breast cancer mortality after longer follow-up periods.  
The RCTs do not directly address whether the magnitude of benefit from screening is sufficient 
to outweigh the harm (e.g., unnecessary biopsies). The risk for false-positive mammography 
results and their consequences is highest in younger women. On the basis of the USPSTF meta-
analysis of more than 10 years of biennial screening among women in their forties, for each 
death from breast cancer prevented, approximately 400 women would have false-positive results 
on mammography and 100 women would undergo biopsy or fine-needle aspiration.6 It is 
important to note that in one cross-sectional survey, 63 percent of women indicated that they 
would accept 500 instances of false-positive results to save one life.9 
One study10 compared the cost-effectiveness of mammography screening in women of various 
age groups. The results of this study concluded that screening women 40 to 49 years of age with 
mammography improved life expectancy by 2.5 days at a cost of $676 per woman, resulting in a 
cost-effectiveness ratio of $105,000 per year of life saved. 
Screening intervals in the clinical trials ranged from 12 to 33 months. The period in which breast 
cancer can be detected before it clinically presents may be shorter in women 40 to 49 years of 
age, suggesting that they should be screened at shorter intervals than older women. However, 
there is no clear evidence from the trials of a difference in mortality reduction related to 
screening interval.2,6 
Recommendations from Others 
Nearly all North American medical organizations support mammography screening, although 
they vary in the recommended age to begin screening and the interval for screening. The 
American Medical Association, American College of Radiology, American Cancer Society, 
American College of Obstetricians and Gynecologists, and the USPSTF all support 
mammography screening beginning at age 40.11-15 
The American Academy of Family Physicians (AAFP) and the Canadian Task Force on 
Preventive Health Care recommend beginning mammography screening in average-risk women 
at age 50, and that all women aged 40 to 49 be counseled about the risks and benefits of 
mammography before making a decision to screen.16,17 The USPSTF recommendations suggest 
"the precise age at which the potential benefits of mammography justify the possible harms is a 
subjective choice."15p1 In addition, the AAFP recommends mammography screening in high-
risk women beginning at age 40.16 
Clinical Commentary 
Because of the controversy about when to begin routine screening, the problems of false-positive 
mammography results, and possible over-diagnosis, patients and their physicians should decide 
together when to start screening. The decision should be made by reviewing patient education 
materials with the patient to help her understand the risks of breast cancer and of false-positive 
mammography results. The AAFP provides a booklet entitled, "Breast Cancer Screening 
Counseling Tools" (available online at http://www.aafp.org/x19498.xml) that can be used during 
the discussion. 
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